PVP Ventures
- Market cap
- ₹ 1,031 Cr.
- P/E
- 68.1x
- P/B
- 4.96x
- 52-week range
- 23 – 72.04
- ROE
- −2%
- ROCE
- 6%
- Dividend yield
- 0%
- Debt / equity
- 1.18
- Sector
- Realty
- Industry
- Residential, Commercial Projects
- Listed on
- NSE, BSE
About
PVP Ventures Limited is an India-based company, which is engaged in the business of health care services and developing urban infrastructure and investments in various ventures. The Company’s segments include Real Estate, Health Care Services and Others. It offers healthcare services across a spectrum of offerings driven entirely through inorganic growth. Its focus areas include cancer care, senior care, teleradiology, dialysis, and diagnostics, including genomics. The Company’s brands include Orange Imaging & Diagnostics, DOC Medical Services and Humain Sai Labs. Its subsidiaries include PVP Corporate Parks Private Limited, Safetrunk Services Private Limited, Humain Healthtech Private Limited, Noble Diagnostics Private Limited and Apta Medical Imaging Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Residential, Commercial Projects: 174 companies →PVP Ventures against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)68.1 against a typical 23.3: pricier than most peers (1st = cheapest).131st of 173
- Sales growth+170.6% against a typical +6.6% from a year earlier.19th of 134
- Share price, 3 months+68.5% against a typical −9.9%.2nd of 147
- Size₹ 1,031.2 Cr. market value against a typical ₹ 129.6 Cr. (1st = largest).41st of 163
Latest announcements
Exchange filings and their impact on the company.
- Signed non-binding LOI for 10 Elekta LINACs worth $11-15m for oncology expansion via subsidiary, phased to Oct 2028.
Evervie Health (formerly PVP Ventures) signed a Letter of Intent on 20 October 2026 with Elekta Solutions AB, Sweden for 10 Harmony linear accelerator systems for cancer treatment. The deal is valued at $11-15 million with phased delivery of 5 plus 5 units by October 2028. The LOI is non-binding and subject to a final purchase agreement, approvals and financing, with the machines to be operated by its subsidiary Optimus Oncology Private Limited.
- Evervie Health paid Rs 13.46 cr NCD interest for Dec 2026 and Mar 2027 six months early, signalling comfortable liquidity.
Evervie Health (formerly PVP Ventures) paid Rs 13.46 crore interest on its Rs 150 crore non-convertible debentures in advance on 8 October 2026. The amount covers the quarterly coupons due on 31 December 2026 and 31 March 2027 for Series A of Rs 95 crore and Series B of Rs 55 crore. Paying six months early confirms timely servicing with no delay or default and has no extra cost beyond timing of cash outflow.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BBB- to BB by 2 agencies- The agencies don't fully agree: Acuite says BBB-, Brickwork says BB.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Brickwork | BWR BB | Stable | 11 Sep 2026 |
| Acuite | ACUITE BBB- | Stable | 2 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 11 Sep 2026 | ▲ Outlook raised | BWR BB Outlook Negative → Stable | — | Brickwork | ₹ 150 Cr. | |
| 2 Sep 2026 | New rating | ACUITE BBB- | — | Acuite | ₹ 150 Cr. | |
| 15 Jul 2026 | Reaffirmed | BWR BB + | — | Brickwork | ₹ 150 Cr. | |
| 9 Jun 2026 | Reaffirmed | BWR BB + | — | Brickwork | ₹ 300 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 23 Feb 2026 | Financial Results | PVP : 23-Feb-2026 : The Company has informed the Exchange that a Board meeting to be held on February 12, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on February 23, 2026, To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results/Other business matters | To consider and approve the unaudited standalone & consolidated financial results for the period ended September 30, 2025 and other business matters |
| 20 Aug 2025 | Financial Results | PVP : 20-Aug-2025 : The Company has informed the Exchange that a Board meeting to be held on August 13, 2025 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on August 20, 2025, To consider and approve the financial results for the period ended Jun 30, 2025 |
| 13 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 4 | 4 | 3 | 3 | 2 | 19 | 17 | 17 | 14 | 41 | 46 |
| Expenses | 3 | 7 | 7 | 6 | 8 | 7 | 14 | 12 | 15 | 10 | 34 | 32 |
| Operating Profit | −3 | −3 | −3 | −4 | −5 | −4 | 5 | 5 | 2 | 4 | 7 | 13 |
| OPM % | −10,867% | −59% | −87% | −143% | −154% | −172% | 27% | 29% | 14% | 28% | 17% | 29% |
| Other Income | 0 | 73 | 7 | 3 | 3 | 3 | −4 | 4 | 4 | 3 | 9 | 15 |
| Interest | 1 | 3 | 1 | 1 | 1 | 0 | 1 | 8 | 8 | 8 | 9 | 10 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 10 | 6 |
| Profit before tax | −4 | 67 | 2 | −3 | −4 | −3 | 0 | 0 | −4 | −2 | −2 | 12 |
| Tax % | 0% | 0% | −202% | −17% | −20% | −71% | 1,528% | −78% | −27% | 119% | 28% | 8% |
| Net Profit | −4 | 67 | 7 | −2 | −3 | −1 | −3 | 0 | −3 | −4 | −3 | 11 |
| EPS in Rs | −0.01 | 2.59 | 0.28 | −0.08 | −0.1 | −0.02 | −0.06 | 0.01 | −0.12 | −0.14 | −0.01 | 0.46 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −5%
- 5 Years
- 38%
- 3 Years
- −20%
- TTM
- 182%
- 10 Years
- 5%
- 5 Years
- 14%
- 3 Years
- —
- TTM
- 906%
- 10 Years
- 25%
- 5 Years
- 54%
- 3 Years
- 63%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| PVP Ventures | ₹ 45.96 | ₹ 1,031 Cr. | 68.1x | 5x | −2% | — |
| Prestige Estates Projects | ₹ 1,400.00 | ₹ 60,302 Cr. | 61x | 4.5x | 7.5% | 10.3% |
| Embassy Office Parks REIT | ₹ 422.00 | ₹ 40,001 Cr. | 54.6x | 2.1x | 4.3% | 20.3% |
| Nexus Select Trust | ₹ 158.12 | ₹ 23,955 Cr. | 62.2x | 1.9x | 3% | 15.7% |
| WeWork India Management | ₹ 630.90 | ₹ 8,782 Cr. | 62.8x | 30.8x | — | 3.2% |
| NESCO | ₹ 988.20 | ₹ 6,963 Cr. | 18.4x | 2.6x | 14.7% | 44.3% |
Management
- Prasad Veera Potluri
- Chairman of the Board, Managing Director
- Raghu Chaitanya
- Chief Financial Officer
- Neeraja Nagarajan
- Chief Operating Officer, Additional Director
- B. Vignesh Ram
- Company Secretary and Compliance officer
- Dileep Badey
- Whole-Time Director
- Sai Padma Potluri
- Additional Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.